Premium
P1‐041: 24‐MONTH ANALYSIS OF APOE ε4 CARRIERS IN PRIME: A RANDOMIZED PHASE 1B STUDY OF THE ANTI–AMYLOID BETA MONOCLONAL ANTIBODY ADUCANUMAB
Author(s) -
Rosenstiel Philip,
Castrillo-Viguera Carmen,
Gheuens Sarah,
Chen Tianle,
O'Gorman John,
Chiao Ping,
Wang Guanfang,
Hehn Christian,
Skordos LeAnne,
Hock Christoph,
Nitsch Roger M.,
Haeberlein Samantha Budd,
Sandrock Alfred
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - Italian
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.042
Subject(s) - placebo , medicine , randomized controlled trial , clinical endpoint , adverse effect , placebo controlled study , gastroenterology , double blind , pathology , alternative medicine
P1-041 24-MONTH ANALYSIS OFAPOE ε4 CARRIERS IN PRIME: A RANDOMIZED PHASE 1B STUDYOF THEANTI–AMYLOID BETA MONOCLONAL ANTIBODY ADUCANUMAB Philip von Rosenstiel, Carmen Castrillo-Viguera, Sarah Gheuens, Tianle Chen, John O’Gorman, Ping Chiao, Guanfang Wang, Christian von Hehn, LeAnne Skordos, Christoph Hock, RogerM. Nitsch, Samantha Budd Haeberlein, Alfred Sandrock, Biogen, Cambridge, MA, USA; Cytel, Cambridge, MA, USA; Neurimmune Holding AG, Zurich, Switzerland. Contact e-mail: philipp.vonrosenstiel@ biogen.com